Barclays PLC Allakos Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Allakos Inc. stock. As of the latest transaction made, Barclays PLC holds 869,969 shares of ALLK stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

869,969

Previous 869,969 -0.0%

Holding current value

$1.12 Million

Previous $568,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$0.54 - $0.92 $142,586 - $242,925	-264,049 Reduced 23.28%	869,969 $568,000
Q2 2024 Aug 14, 2024	SELL	$1.0 - $1.45 $25,336 - $36,737	-25,336 Reduced 2.19%	1,134,018 $1.13 Million
Q1 2024 May 15, 2024	BUY	$1.02 - $3.23 $1.09 Million - $3.45 Million	1,068,057 Added 1169.87%	1,159,354 $1.46 Million
Q4 2023 Feb 15, 2024	SELL	$1.72 - $3.18 $546,390 - $1.01 Million	-317,669 Reduced 77.68%	91,297 $249,000
Q3 2023 Nov 07, 2023	SELL	$2.13 - $5.55 $205,076 - $534,354	-96,280 Reduced 19.06%	408,966 $928,000
Q2 2023 Aug 03, 2023	BUY	$3.6 - $5.25 $161,704 - $235,819	44,918 Added 9.76%	505,246 $2.2 Million
Q1 2023 May 04, 2023	BUY	$4.3 - $8.27 $242,958 - $467,271	56,502 Added 13.99%	460,328 $2.05 Million
Q4 2022 Feb 13, 2023	BUY	$5.66 - $8.42 $2.15 Million - $3.19 Million	379,451 Added 1556.72%	403,826 $3.4 Million
Q3 2022 Nov 03, 2022	BUY	$3.02 - $6.12 $41,624 - $84,351	13,783 Added 130.13%	24,375 $150,000
Q2 2022 Aug 12, 2022	SELL	$2.6 - $6.14 $62,111 - $146,678	-23,889 Reduced 69.28%	10,592 $33,000
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $89,245 - $172,342	-17,568 Reduced 33.75%	34,481 $196,000
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $271,300 - $3.55 Million	31,731 Added 156.17%	52,049 $509,000
Q3 2021 Nov 09, 2021	BUY	$76.53 - $110.43 $491,399 - $709,071	6,421 Added 46.2%	20,318 $2.15 Million
Q2 2021 Aug 13, 2021	SELL	$85.37 - $114.1 $3.49 Million - $4.66 Million	-40,883 Reduced 74.63%	13,897 $1.19 Million
Q1 2021 May 13, 2021	BUY	$109.73 - $153.66 $614,378 - $860,342	5,599 Added 11.38%	54,780 $6.29 Million
Q4 2020 Feb 11, 2021	SELL	$79.58 - $152.45 $205,316 - $393,320	-2,580 Reduced 4.98%	49,181 $6.89 Million
Q3 2020 Nov 12, 2020	BUY	$66.43 - $90.99 $2.53 Million - $3.46 Million	38,014 Added 276.53%	51,761 $4.22 Million
Q2 2020 Aug 12, 2020	SELL	$44.04 - $80.69 $939,549 - $1.72 Million	-21,334 Reduced 60.81%	13,747 $987,000
Q1 2020 May 13, 2020	BUY	$44.49 - $93.39 $667,394 - $1.4 Million	15,001 Added 74.71%	35,081 $1.56 Million
Q4 2019 Feb 10, 2020	BUY	$66.49 - $137.73 $542,225 - $1.12 Million	8,155 Added 68.39%	20,080 $1.92 Million
Q3 2019 Nov 14, 2019	SELL	$31.0 - $89.73 $16,678 - $48,274	-538 Reduced 4.32%	11,925 $938,000
Q2 2019 Aug 14, 2019	BUY	$36.0 - $44.73 $200,232 - $248,788	5,562 Added 80.6%	12,463 $541,000
Q1 2019 May 15, 2019	SELL	$33.79 - $51.99 $715,841 - $1.1 Million	-21,185 Reduced 75.43%	6,901 $280,000
Q4 2018 Feb 14, 2019	BUY	$31.59 - $62.65 $12,193 - $24,182	386 Added 1.39%	28,086 $1.47 Million
Q3 2018 Nov 14, 2018	BUY	$31.25 - $47.64 $865,625 - $1.32 Million	27,700 New	27,700 $1.25 Million

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $109M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account